LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Elenco Azioni・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

10.45 -7.11

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.45

Massimo

11.21

Metriche Chiave
By Trading Economics
Entrata	227M
Vendite	139M
P/E Media del settore	4.302 49.888
Margine di Profitto	163.843
Dipendenti	1,796
EBITDA	1.3M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+48.54% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	2B
Apertura precedente	17.56
Chiusura precedente	10.45

Notizie sul Sentiment di mercato

By Acuity

10%

90%

9 / 344 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 giu 2026, 21:51 UTC

I principali Market Mover

Merlin Shares Rally After Defense Department's Design Review Wraps

4 giu 2026, 23:46 UTC

Discorsi di Mercato

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 giu 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 giu 2026, 23:42 UTC

Acquisizioni, Fusioni, Takeovers

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 giu 2026, 23:41 UTC

Acquisizioni, Fusioni, Takeovers

Energy Resources of Australia to Enter Trading Halt

4 giu 2026, 23:34 UTC

Discorsi di Mercato

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 giu 2026, 23:31 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

4 giu 2026, 23:08 UTC

Discorsi di Mercato

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 giu 2026, 22:41 UTC

Discorsi di Mercato

Australia Shares Set to Rise at the Open -- Market Talk

4 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

4 giu 2026, 20:44 UTC

Acquisizioni, Fusioni, Takeovers

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 giu 2026, 20:16 UTC

Discorsi di Mercato

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 giu 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 giu 2026, 19:46 UTC

Discorsi di Mercato

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 giu 2026, 19:38 UTC

Discorsi di Mercato

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 giu 2026, 19:30 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 giu 2026, 18:47 UTC

Acquisizioni, Fusioni, Takeovers

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 giu 2026, 18:38 UTC

Utili

Money Quote: Tech Weakness in Context -- WSJ

4 giu 2026, 18:24 UTC

Utili

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 giu 2026, 17:09 UTC

Discorsi di Mercato

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 giu 2026, 16:58 UTC

Utili

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 giu 2026, 16:46 UTC

Discorsi di Mercato

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 giu 2026, 16:38 UTC

Utili

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 giu 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

4 giu 2026, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

4 giu 2026, 16:13 UTC

Discorsi di Mercato

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 giu 2026, 16:11 UTC

Discorsi di Mercato

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 giu 2026, 15:56 UTC

Discorsi di Mercato

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

48.54% in crescita

Previsioni per 12 mesi

Media 16.8 USD 48.54%

Alto 20 USD

Basso 13.6 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 2 che hanno fornito valutazioni azionarie a Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

9 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.